• Citer

HER-2 overexpression/amplification and its interaction with taxane-based therapy in breast cancer.

par de Azambuja, Evandro ;Durbecq, Virginie ;Rosa, Daniela D;Colozza, Mariantonietta;Larsimont, Denis ;Piccart-Gebhart, Martine ;Cardoso, Fatima
Référence Annals of oncology, 19, 2, page (223-232)
Publication Publié, 2008-02

Article révisé par les pairs

• Accès en ligne
• Détails
• Contenu
• Statistiques

Titre:	HER-2 overexpression/amplification and its interaction with taxane-based therapy in breast cancer.
Auteur:	de Azambuja, Evandro; Durbecq, Virginie; Rosa, Daniela D; Colozza, Mariantonietta; Larsimont, Denis; Piccart-Gebhart, Martine; Cardoso, Fatima
Informations sur la publication:	Annals of oncology, 19, 2, page (223-232)
Statut de publication:	Publié, 2008-02
Sujet CREF:	Sciences bio-médicales et agricoles
Mots-clés:	Breast cancer
	ECD
	HER-2 overexpression
	Taxane resistance
	Trastuzumab
MeSH keywords:	Antibodies, Monoclonal -- administration & dosage
	Antineoplastic Combined Chemotherapy Protocols -- administration & dosage
	Breast Neoplasms -- drug therapy
	Breast Neoplasms -- genetics
	Breast Neoplasms -- mortality
	Breast Neoplasms -- surgery
	Chemotherapy, Adjuvant
	Clinical Trials, Phase II as Topic
	Clinical Trials, Phase III as Topic
	Drug Resistance, Neoplasm
	Female
	Gene Expression Regulation, Neoplastic
	Humans
	Immunohistochemistry
	Mastectomy -- methods
	Neoplasm Staging
	Paclitaxel -- administration & dosage
	Predictive Value of Tests
	Prognosis
	Randomized Controlled Trials as Topic
	Receptor, erbB-2 -- genetics
	Receptor, erbB-2 -- metabolism
	Risk Assessment
	Sensitivity and Specificity
	Survival Analysis
	Taxoids -- administration & dosage
	Treatment Outcome
	Tumor Markers, Biological -- analysis
Note générale:	Journal Article
	Research Support, Non-U.S. Gov't
	Review
Langue:	Anglais
Identificateurs:	urn:issn:0923-7534
	info:doi/10.1093/annonc/mdm352
	info:pii/mdm352
	info:scp/38849127396
	info:pmid/17872901